1. Rudolf Magnus Institute for Neurosciences, Section of Molecular Neuroscience, Department of Medical Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands; School of Biological Sciences, University of Manchester, Manchester, and Molecular Neuroendocrinology Research Group, Department of Medicine, University of Bristol, Bristol, United Kingdom; and Laboratory of Neurochemistry, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland